Pfizer and biontech announce positive topline data for mrna-based combination vaccine program against influenza and covid-19

New york and mainz, germany, october 26, 2023 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced positive topline results from a phase 1/2 study ( nct05596734 ) evaluating the safety, tolerability and immunogenicity of mrna-based combination vaccine candidates for influenza and covid-19 among healthy adults 18 to 64 years of age. in the clinical trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies' omicron ba.4/ba.5-adapted bivalent covid-19 vaccine given at the same visit. the data from the trial showed that the companies' lead formulations demonstrated robust immune responses to influenza a, influenza b, and sars-cov-2 strains.
BNTX Ratings Summary
BNTX Quant Ranking